UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13D
(Amendment No. 4)*
Under the Securities Exchange Act of 1934
|
ZIOPHARM ONCOLOGY, INC.
|
|
(Name of Issuer)
|
|
Common Stock, par value $0.001 per share
|
|
(Title of Class of Securities)
|
|
98973P101
|
|
(CUSIP Number)
|
|
Third Security, LLC
1881 Grove Avenue
Radford, Virginia 24141
Attention: Marcus E. Smith, Esq.
(540) 633-7900
|
|
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
|
|
Copy to:
Intrexon Corporation
Attention: Legal
20358 Seneca Meadows Parkway
Germantown, Maryland 20876
(301) 556-9809
|
|
November 7, 2012
|
|
(Date of Event which Requires Filing of this Statement)
|
If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box o.
NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| CUSIP No. 89365K206 |
Page 2 of 7
|
|
1
|
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
Randal J. Kirk
|
|
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF GROUP
|
|
|
3
|
SEC USE ONLY
|
|
|
4
|
SOURCE OF FUNDS
PF
|
|
|
5
|
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEM 2(d) OR 2(e)
|
o |
|
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
|
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
||
|
7
|
SOLE VOTING POWER
|
|
|
50,911
|
||
|
8
|
SHARED VOTING POWER
|
|
|
14,879,624
|
||
|
9
|
SOLE DISPOSITIVE POWER
|
|
|
50,911
|
||
|
10
|
SHARED DISPOSITIVE POWER
14,879,624
|
| CUSIP No. 98973P101 |
Page 3 of 7
|
|
1
|
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
Intrexon Corporation
I.R.S. IDENTIFICATION NO.: 26-0084895
|
|
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF GROUP
(a) o
(b) x
|
|
|
3
|
SEC USE ONLY
|
|
|
4
|
SOURCE OF FUNDS
WC
|
|
|
5
|
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEM 2(d) OR 2(e)
|
o |
|
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Virginia
|
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
||
|
7
|
SOLE VOTING POWER
|
|
|
0
|
||
|
8
|
SHARED VOTING POWER
|
|
|
13,533,162
|
||
|
9
|
SOLE DISPOSITIVE POWER
|
|
|
0
|
||
|
10
|
SHARED DISPOSITIVE POWER
13,533,162
|
|
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
13,533,162
|
|
|
12
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES
|
o |
|
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
16.3%
|
|
|
14
|
TYPE OF REPORTING PERSON
CO
|
| CUSIP No. 98973P101 |
Page 4 of 7
|
This Amendment No. 4 (the “Amendment”) amends and supplements the Statement on Schedule 13D, dated January 12, 2011 and filed on January 20, 2011, as amended by Amendment No. 1 dated February 3, 2011 and filed on February 11, 2011, Amendment No. 2 dated August 9, 2011 and filed on August 16, 2011, and Amendment No. 3 dated January 20, 2012 and filed on January 25, 2012 (the “Original Schedule 13D”), relating to the Common Stock, par value $0.001 per share (the “Common Stock”), of ZIOPHARM Oncology, Inc., a Delaware corporation (the “Company”). Mr. Randal J. Kirk (“Mr. Kirk”) and Intrexon Corporation, a Virginia corporation (“Intrexon” and, together with Mr. Kirk, the “Reporting Persons”), are filing this Amendment to disclose the acquisition by Intrexon, an affiliate of Mr. Kirk, of 3,636,926 shares of Common Stock in a private placement in connection with the satisfaction of a contingency contained in the Exclusive Channel Partner Agreement between Intrexon and the Company dated January 6, 2011 (the “Channel Agreement”). Mr. Kirk could be deemed to have indirect beneficial ownership of the shares of Common Stock directly beneficially owned by Intrexon and Kapital Joe, LLC (“Kapital Joe”), an affiliate of Mr. Kirk that also owns shares of Common Stock disclosed herein.
Except as set forth below, there are no changes to the information set forth in the Original Schedule 13D.
| CUSIP No. 98973P101 |
Page 5 of 7
|
Item 3 of the Original Schedule 13D is hereby amended and supplemented as follows:
In the Channel Agreement the Company agreed to issue additional shares of Common Stock to Intrexon upon dosing of the first patient in a ZIOPHARM-conducted Phase II clinical trial in the United States, or similar study as the parties may agree in a country other than the United States, of a product that is created, produced, developed or identified directly or indirectly by the Company during the term of the Channel Agreement and that, subject to certain exceptions, involves DNA administered to humans for expression of anti-cancer effectors for the purpose of treatment or prophylaxis of cancer. Upon satisfaction of such contingency, the Company issued to Intrexon on November 7, 2012 an additional 3,636,926 shares of Common Stock (the “Second Tranche Shares”), in accordance with the Channel Agreement.
|
Item 5.
|
Interest in Securities of the Issuer.
|
Items 5(a) and (b) of the Original Schedule 13D are hereby amended and restated to read in their entirety as follows:
(a) and (b) See Items 11 and 13 of the cover pages to this Statement for the aggregate number of shares and percentage of issued and outstanding shares of Common Stock of the Company owned by the Reporting Persons. The percentage ownership is calculated based on 79,619,597 shares of Common Stock issued and outstanding as of October 26, 2012, based upon the number of shares disclosed by the Company as of such date in its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2012, plus 3,636,926 shares issued as the Second Tranche Shares and 8,334 shares of Common Stock issuable upon exercise of stock options directly owned by Mr. Kirk that are currently exercisable.
|
Reporting Person
|
Amount of
Common Stock
Beneficially
Owned
|
Percent
of Class
|
Sole Power
to Vote or
Direct
the Vote
|
Shared
Power to
Vote or
Direct
the Vote
|
Sole Power to
Dispose or to
Direct the
Disposition
|
Shared Power to
Dispose or to
Direct the
Disposition
|
||||||||||||
|
Randal J. Kirk
|
14,930,535 | 17.9% | 50,911 | 14,879,624(1) | 50,911 | 14,879,624(1) | ||||||||||||
|
Intrexon Corporation
|
13,533,162 | 16.3% | — | 13,533,162 | — | 13,533,162 |
|
|
(1)
|
Includes 13,533,162 shares of Common Stock held by Intrexon and 1,346,462 shares of Common Stock held by Kapital Joe.
|
Mr. Kirk could be deemed to have indirect beneficial ownership of the shares of Common Stock directly beneficially owned by Intrexon and Kapital Joe.
|
Item 6.
|
Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
|
The Reporting Persons’ responses to Items 3 and 4 are incorporated herein by reference.
| CUSIP No. 98973P101 |
Page 6 of 7
|
|
Item 7.
|
Material to be Filed as Exhibits.
|
|
Exhibit 1
|
Joint Filing Agreement, dated as of November 9, 2012, by and between Mr. Kirk and Intrexon
|
| CUSIP No. 98973P101 |
Page 7 of 7
|
SIGNATURES
After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.
Date: November 9, 2012
|
/s/ Randal J. Kirk
|
|||
|
Randal J. Kirk
|
|||
|
INTREXON CORPORATION
|
|||
|
By:
|
/s/ Randal J. Kirk
|
||
|
Randal J. Kirk
|
|||
|
Chief Executive Officer
|
|||
EXHIBIT INDEX
|
Joint Filing Agreement, dated as of November 9, 2012, by and between Mr. Kirk and Intrexon
|
Exhibit 1
Joint Filing Agreement
In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them a Statement on Schedule 13D (including amendments thereto) with regard to the common stock of ZIOPHARM Oncology, Inc., and further agree that this Joint Filing Agreement be included as an exhibit to such joint filings. In evidence thereof, the undersigned, being duly authorized, hereby execute this agreement as of the 9th day of November, 2012.
|
/s/ Randal J. Kirk
|
|||
|
Randal J. Kirk
|
|||
|
INTREXON CORPORATION
|
|||
|
By:
|
/s/ Randal J. Kirk
|
||
|
Randal J. Kirk
|
|||
|
Chief Executive Officer
|
|||